{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:08:46Z","timestamp":1789711726812,"version":"4.0.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality worldwide and is characterized by substantial molecular and immunologic heterogeneity that contributes to therapeutic resistance and poor clinical outcomes. Glypican-3 (GPC3) is an attractive immunotherapy target in HCC; however, its heterogeneous expression limits the effectiveness of GPC3-directed approaches. ECT204, a GPC3-directed ARTEMIS\n                      <jats:sup>\u00ae<\/jats:sup>\n                      T-cell therapy, has shown improved safety compared with conventional CAR T cells but remains dependent on sufficient tumor-associated GPC3 expression. In this study, we investigated whether an oncolytic virus could be used to selectively deliver GPC3 to tumor cells to expand the applicability of GPC3-targeted immunotherapies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We engineered the oncolytic vaccinia virus CF33-GPC3 to express GPC3 and evaluated its ability to sensitize GPC3-negative tumor cells to ECT204\n                      <jats:italic>in vitro<\/jats:italic>\n                      and\n                      <jats:italic>in vivo<\/jats:italic>\n                      using GPC3-knockout HepG2 xenograft models. We also assessed the compatibility with other GPC3-targeted immunotherapies, including a bispecific T-cell engager (BiTE) and the monoclonal antibody codrituzumab.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CF33-GPC3 efficiently induced surface expression of GPC3 in previously GPC3-negative tumor cells, resulting in activation of GPC3-directed ECT204 T cells and subsequent tumor cell killing.\n                      <jats:italic>In vivo<\/jats:italic>\n                      , combination therapy with CF33-GPC3 and ECT204, administered either intratumorally or intravenously, achieved significantly greater tumor control than either monotherapy alone. Moreover, OV-mediated GPC3 expression sensitized tumor cells to killing by GPC3-specific BiTE-redirected T cells and enhanced codrituzumab-mediated NK cell cytotoxicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings demonstrate that OV-mediated GPC3 delivery can overcome antigen heterogeneity in HCC and broaden the applicability of GPC3-directed immunotherapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1894178","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:36:13Z","timestamp":1789709773000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncolytic virus\u2013mediated GPC3 delivery overcomes antigen heterogeneity in hepatocellular carcinoma and enhances GPC3-directed immunotherapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Shyambabu","family":"Chaurasiya","sequence":"first","affiliation":[{"name":"Depratment of Surgery, City of Hope National Medical Center","place":["Duarte, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-In","family":"Kim","sequence":"additional","affiliation":[{"name":"Depratment of Surgery, City of Hope National Medical Center","place":["Duarte, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Sah","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Molecular Genetics, Oklahoma State University","place":["Stillwater, OK, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Depratment of Surgery, City of Hope National Medical Center","place":["Duarte, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoya","family":"Vashi","sequence":"additional","affiliation":[{"name":"Depratment of Surgery, City of Hope National Medical Center","place":["Duarte, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Wu","sequence":"additional","affiliation":[{"name":"Depratment of Surgery, City of Hope National Medical Center","place":["Duarte, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Cillis","sequence":"additional","affiliation":[{"name":"Depratment of Surgery, City of Hope National Medical Center","place":["Duarte, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Park","sequence":"additional","affiliation":[{"name":"Depratment of Surgery, City of Hope National Medical Center","place":["Duarte, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Yang","sequence":"additional","affiliation":[{"name":"Depratment of Surgery, City of Hope National Medical Center","place":["Duarte, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanghee","family":"Woo","sequence":"additional","affiliation":[{"name":"Depratment of Surgery, City of Hope National Medical Center","place":["Duarte, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyang","family":"Xiong","sequence":"additional","affiliation":[{"name":"Eureka Therapeutics Inc","place":["Emeryville, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbao","family":"Liu","sequence":"additional","affiliation":[{"name":"Eureka Therapeutics Inc","place":["Emeryville, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Eureka Therapeutics Inc","place":["Emeryville, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Wang","sequence":"additional","affiliation":[{"name":"Eureka Therapeutics Inc","place":["Emeryville, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Eureka Therapeutics Inc","place":["Emeryville, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuman","family":"Fong","sequence":"additional","affiliation":[{"name":"Depratment of Surgery, City of Hope National Medical Center","place":["Duarte, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12450","article-title":"Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States","volume":"38","author":"Tan","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.45525","article-title":"Trends in hepatocellular carcinoma mortality rates in the US and projections through 2040","volume":"7","author":"Qiu","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4930","article-title":"Systemic therapy and sequencing options in advanced hepatocellular carcinoma: A systematic review and network meta-analysis","volume":"6","author":"Sonbol","year":"2020","journal-title":"JAMA Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.01.007","article-title":"Precision treatment in advanced hepatocellular carcinoma","volume":"42","author":"Yang","year":"2024","journal-title":"Cancer Cell"},{"key":"B6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-024-01639-1","article-title":"Advances in CAR-T cell therapy for hematologic and solid Malignancies: latest updates from 2024 ESMO Congress","volume":"17","author":"Huang","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","article-title":"Bispecific T cell engagers: an emerging therapy for management of hematologic Malignancies","volume":"14","author":"Tian","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: Tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01936","article-title":"Monoclonal antibody therapies for hematological Malignancies: Not just lineage-specific targets","volume":"8","author":"Cuesta-Mateos","year":"2017","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-0612","article-title":"FDA approval: blinatumomab","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.46989\/001c.124277","article-title":"Overview of approved CAR-T products and utility in clinical practice","volume":"6","author":"Bhaskar","year":"2024","journal-title":"Clin Hematol Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-00992-5","article-title":"Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma","volume":"22","author":"Bock","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7150\/jca.39972","article-title":"Glypican-3: A new target for diagnosis and treatment of hepatocellular carcinoma","volume":"11","author":"Guo","year":"2020","journal-title":"J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.824208","article-title":"Glypican-3: A novel and promising target for the treatment of hepatocellular carcinoma","volume":"12","author":"Zheng","year":"2022","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1080\/14728222.2024.2416975","article-title":"Progress and challenges in glypican-3 targeting for hepatocellular carcinoma therapy","volume":"28","author":"Couzinet","year":"2024","journal-title":"Expert Opin Ther Targets"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2010.10.004","article-title":"Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma","volume":"15","author":"Yan","year":"2011","journal-title":"Ann Diagn Pathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2024.2796","article-title":"Evaluation of glypican-3 in patients with hepatocellular carcinoma","volume":"22","author":"Batbaatar","year":"2025","journal-title":"Mol Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-021-01067-5","article-title":"CAR-T cells and BiTEs in solid tumors: challenges and perspectives","volume":"14","author":"Edeline","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol Cell Biol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41421-018-0066-6","article-title":"A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma\/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release","volume":"4","author":"Xu","year":"2018","journal-title":"Cell Discov"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04132-9","article-title":"A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed\/refractory B-cell lymphoma","volume":"149","author":"He","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nri888","article-title":"Viruses and interferon: a fight for supremacy","volume":"2","author":"Katze","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"15","author":"Kaufman","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"B25","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12967-018-1483-x","article-title":"Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose","volume":"16","author":"O'Leary","year":"2018","journal-title":"J Transl Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv1507","article-title":"TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data","volume":"44","author":"Colaprico","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2023.2269637","article-title":"Antibody dependent cell-mediated cytotoxicity selection pressure induces diverse mechanisms of resistance","volume":"24","author":"Zahavi","year":"2023","journal-title":"Cancer Biol Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.004","article-title":"Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma","volume":"65","author":"Abou-Alfa","year":"2016","journal-title":"J Hepatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00262-025-04039-7","article-title":"Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression","volume":"74","author":"Aboalela","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz1863","article-title":"Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors","volume":"12","author":"Park","year":"2020","journal-title":"Sci Transl Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","article-title":"Mesothelin targeted cancer immunotherapy","volume":"44","author":"Hassan","year":"2008","journal-title":"Eur J Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30646","article-title":"A Frizzled-Like Cysteine-Rich Domain in Glypican-3 mediates Wnt binding and regulates hepatocellular carcinoma tumor growth in mice","volume":"70","author":"Li","year":"2019","journal-title":"Hepatology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/v14020431","article-title":"Vaccinia virus arrests and shifts the cell cycle","volume":"14","author":"Martin","year":"2022","journal-title":"Viruses"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1894178\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:36:14Z","timestamp":1789709774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1894178\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2026.1894178"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1894178","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1894178"}}